Cytotoxic T-cell epitopes of HIV-1 virus
OwnerMarcus Altfeld, Xu Yu +2inventors
InventorsMarcus Altfeld, Xu Yu, Bruce D. Walker, Marylyn Addo
Life of this patent
Estimating the term…
Abstract
The invention provides compositions containing HIV epitopes, which are recognized by cytotoxic T lymphocytes (CTL). Such polypeptides are used in vaccines and immunotherapies. HIV-1 epitopes represent early targets in a naturally-occurring response against HIV-1 infection.
Claims20
An immunogenic composition comprising an HLA class I restricted HIV-1 polypeptide, wherein said polypeptide consists essentially of 8-12 amino acids and wherein said peptide is characterized as an early CTL target in HIV-1 infection.
An immunogenic composition comprising an HLA class I A3-restricted HIV-1 polypeptide, said polypeptide comprising less than 50 amino acids in length, wherein the amino acid sequence of said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, 4, 6, 7, 8, 11, 12, 13, 14, and 15.
An immunogenic composition comprising an HLA class I A3-restricted HIV-1 polypeptide, wherein said polypeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, 4, 6, 7, 8, 11, 12, 13, 14, and 15.
An immunogenic composition comprising an HLA class I B7-restricted HIV-1 polypeptide, said polypeptide comprising less than 50 amino acids in length, wherein the amino acid sequence of said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 18, 25, and 26.
An immunogenic composition comprising an HLA class I B7-restricted HIV-1 polypeptide, wherein said polypeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 18, 25 and 26.
An immunogenic composition comprising an HLA class I Cw7-restricted HIV-1 polypeptide, said polypeptide comprising less than 50 amino acids in length, wherein the amino acid sequence of said polypeptide comprises the amino acid sequence of SEQ ID NO:27.
An immunogenic composition comprising a first polypeptide comprising an amino acid selected from the group consisting of SEQ ID NO:
- 3, 4, 6, 7, 8, 11, 12, 13, 14, 15, 18, 25, 26, and 27, and a second polypeptide comprising an amino acid selected from the group consisting of SEQ ID NO:
- 1, 2, 5, 9, 10, 16, 17, 19, 20, 21, 22, 23, and 24, wherein the length of said first and said second polypeptides is less than 50 amino acids.
A method of stimulating an HIV-specific immune response, comprising contacting an immune cell with an immunogen comprising a polypeptide, wherein said polypeptide is less than 50 amino acids in length and comprises an epitope selected from the group consisting of the amino acid sequence of SEQ ID NO:
- 3, 4, 6, 7, 8, 11, 12, 13, 14, 15, 18, 25, 26, and 27.
A method of stimulating an HIV-specific immune response, comprising administering to a mammal an immunize comprising a peptide epitope selected from the group consisting of SEQ ID NO:
- 3, 4, 6, 7, 8, 11, 12, 13, 14, 15, 18, 25, 26, and 27, wherein said immune response comprises an increase in proliferation of HIV-specific CD8+ T cells.
A method of stimulating an HIV-specific immune response, comprising administering to a member of an asian race an immunogen comprising a peptide epitope selected from the group consisting of SEQ ID NO:
- 5, 6, 8, 10 and 11, wherein said immune response comprises an increase in proliferation of HIV-specific CD8+ T cells.
Dependencies are inferred from the claim text.